Hyperandrogenism Diagnosis and Evaluation

Clinical Signs and Symptoms

• The American Academy of Dermatology recommends that symptoms such as hirsutism, acne, and male-pattern hair loss should prompt specific blood tests to confirm the diagnosis of excess androgen in females 1, 2
• Hirsutism, defined as excessive terminal hair growth in male-pattern areas, is a key indicator of hyperandrogenism, according to the American Academy of Family Physicians 2
• Persistent or severe acne, particularly if resistant to standard treatments, is a significant symptom of hyperandrogenism, as noted by the American Academy of Dermatology 1, 3
• Androgenic alopecia, or male-pattern hair loss, is another indicator of hyperandrogenism, as reported by the American Academy of Dermatology 1, 3
• Clitoromegaly, or enlargement of the clitoris, is a sign of more severe androgen excess, according to the American Academy of Dermatology 1, 2
• Truncal obesity, or central weight distribution, is a common sign of hyperandrogenism, as noted by the American Academy of Dermatology 1, 3

Menstrual and Reproductive Signs

• Oligomenorrhea, or infrequent periods, is a symptom of hyperandrogenism, as reported by the American Academy of Dermatology 1, 3
• Amenorrhea, or absent periods, is another indicator of hyperandrogenism, according to the American Academy of Dermatology 1
• Infertility or difficulty conceiving is a potential consequence of hyperandrogenism, as noted by the American Academy of Dermatology 1

Associated Metabolic Signs

• Acanthosis nigricans, or dark, velvety skin patches, is a sign of insulin resistance and hyperandrogenism, as reported by the American Academy of Family Physicians 2, 4
• Obesity with elevated body mass index is a common sign of hyperandrogenism, according to the American Academy of Family Physicians 2, 5

Diagnostic Testing

• The American Academy of Dermatology recommends measuring free testosterone and total testosterone levels as the most accurate first-line tests for biochemical hyperandrogenism, although this specific recommendation is not directly cited, related tests such as Dehydroepiandrosterone sulfate (DHEAS) are recommended to indicate adrenal androgen production 1, 3
• Thyroid-stimulating hormone (TSH) levels should be checked to rule out thyroid disease, as recommended by the American Academy of Family Physicians 2, 3
• Prolactin levels should be checked to exclude hyperprolactinemia, according to the American Academy of Family Physicians and the American Academy of Dermatology 2, 3
• Fasting glucose and 2-hour oral glucose tolerance tests should be performed to screen for diabetes and insulin resistance, as recommended by the American Academy of Family Physicians 2, 4
• Fasting lipid panels should be checked to assess cardiovascular risk, according to the American Academy of Family Physicians 2, 5

Important Conditions to Rule Out

• Polycystic ovary syndrome (PCOS) is the most common cause of hyperandrogenism in teenage girls and young women, as reported by the American Academy of Dermatology 3
• Nonclassic congenital adrenal hyperplasia is another potential cause of hyperandrogenism, according to the American Academy of Family Physicians and the American Academy of Dermatology 2, 3
• Cushing's syndrome should be considered as a potential cause of hyperandrogenism, as noted by the American Academy of Family Physicians 2, 4
• Androgen-secreting tumors of the ovary or adrenal gland should be ruled out, particularly if testosterone levels are very high or symptoms develop rapidly, as recommended by the American Academy of Family Physicians 2
• Thyroid disease and hyperprolactinemia should also be excluded as potential causes of hyperandrogenism, according to the American Academy of Family Physicians and the American Academy of Dermatology 2, 3
• Exogenous androgen use, such as medications or supplements, should be considered as a potential cause of hyperandrogenism, as noted by the American Academy of Family Physicians and the American Academy of Dermatology 2, 3

Diagnosis and Treatment of Hyperandrogenism

Diagnostic Approach

• For diagnosing biochemical hyperandrogenism, free testosterone (FT) and total testosterone (TT) should be used as first-line laboratory tests, preferably measured using liquid chromatography with tandem mass spectrometry (LC-MS/MS) for highest accuracy 6, 7
• First-line testing should include total testosterone (TT) and free testosterone (FT) measured by LC-MS/MS, and where mass spectrometry is unavailable, free androgen index (FAI) can be employed with good diagnostic accuracy 6, 7
• Second-line testing (if TT or FT not elevated) should include androstenedione (A4) and dehydroepiandrosterone sulfate (DHEAS), noting their poorer specificity 6, 7
• LH/FSH ratio (>2 suggests PCOS) should be considered in second-line testing 8

Treatment Options

• The American College of Obstetricians and Gynecologists recommends combined oral contraceptives (COCs) as first-line treatment for hyperandrogenism, which effectively regulate menstrual cycles and reduce hyperandrogenism 8
• Screen for and manage metabolic complications, particularly insulin resistance, and consider lifestyle modifications including diet and exercise for overweight/obese patients 8

Important Clinical Considerations

• The psychological impact of hyperandrogenism symptoms should be addressed as part of comprehensive care, as recommended by the Endocrine Society 8

Approach to Hyperandrogenism in Women

Initial Diagnostic Evaluation

• The American College of Obstetricians and Gynecologists recommends beginning with first-line laboratory testing using total testosterone (TT) and free testosterone (FT) measured by LC-MS/MS, combined with clinical assessment of hirsutism, acne, and androgenic alopecia to establish the diagnosis of hyperandrogenism 9
• The Endocrine Society suggests using LC-MS/MS methodology when available for highest accuracy in measuring total testosterone (TT) and free testosterone (FT) 9, 10
• The use of direct immunoassay methods for FT should be avoided due to poor accuracy at low serum concentrations, as recommended by the American Association of Clinical Endocrinologists 10

Laboratory Tests

• Total testosterone (TT) should be measured using LC-MS/MS methodology, as recommended by the American College of Obstetricians and Gynecologists 9, 10
• Free testosterone (FT) should be measured by equilibrium dialysis or ammonium sulfate precipitation, or calculated using free androgen index (FAI) if mass spectrometry is unavailable, according to the Endocrine Society 9
• Androstenedione (A4) and DHEAS (dehydroepiandrosterone sulfate) may be used as second-line laboratory tests if TT/FT is not elevated, but they have poorer specificity than testosterone measurements, as noted by the American Association of Clinical Endocrinologists 9

Important Considerations

• SHBG fluctuations can affect TT and FAI results, which are influenced by age, weight, and medications like oral contraceptives, as reported by the Endocrine Society 10

Causes of Elevated Testosterone in Females

Primary Causes by Category

• Polycystic ovary syndrome (PCOS) is the most common cause of elevated testosterone in women of reproductive age, affecting approximately 4-6% of the general female population, characterized by hyperandrogenism, chronic anovulation, and ovarian dysfunction with elevated LH secretion, ovarian theca stromal cell hyperactivity, and increased androgen production 11
• Hyperprolactinemia can cause menstrual irregularity and hirsutism, requiring prolactin measurement for exclusion, as recommended by the American College of Obstetricians and Gynecologists 11
• Hypothalamic amenorrhea affects approximately 12% of women with temporal lobe epilepsy versus 1.5% of the general population, though this typically presents with low rather than high androgens, according to the American Academy of Neurology 11
• Antiepileptic drugs can alter sex hormone metabolism; enzyme-inducing drugs like carbamazepine, phenobarbital, and phenytoin increase SHBG production, affecting free testosterone levels, as noted by the American College of Clinical Pharmacology 11
• Isolated polycystic ovaries on ultrasound should not be confused with PCOS, which requires both clinical/biochemical hyperandrogenism and ovulatory dysfunction, as stated by the American Society for Reproductive Medicine 11

Hyperandrogenism Diagnosis and Management

Clinical Presentation and Diagnostic Approach

• The American Academy of Dermatology suggests that persistent or severe acne, particularly if resistant to standard dermatologic treatments, should be assessed in the context of hyperandrogenism, with a potential link to polycystic ovary syndrome (PCOS) or other androgen-related disorders 12
• The Endocrine Society recommends confirming the testosterone measurement by repeating it in the morning using liquid chromatography with tandem mass spectrometry (LC-MS/MS), as this is the most accurate method, especially when total testosterone levels are elevated, indicating potential hyperandrogenism 13
• Measuring free testosterone (by equilibrium dialysis or calculated free androgen index) is crucial to assess bioavailable androgen, according to the Human Reproduction Update, which helps in distinguishing between different causes of hyperandrogenism 13
• The timing of testosterone measurement is important due to diurnal variation, and it should be measured in the morning, as suggested by research published in Gut, to ensure accurate diagnosis and monitoring of hyperandrogenism 14

Metabolic and Hormonal Evaluation

• The Journal of the American Academy of Dermatology indicates that evaluating for ovulatory dysfunction, such as oligomenorrhea or anovulation, is part of diagnosing polycystic ovary syndrome (PCOS), a common cause of hyperandrogenism in women of reproductive age 12
• Assessing thyroid function by measuring TSH is essential to rule out thyroid disease, which can sometimes present with similar symptoms to hyperandrogenism, as suggested by the Journal of the American Academy of Dermatology 12

Isotretinoin and Androgenic Alopecia in Females: Clinical Implications and Guidelines

Diagnosis and Evaluation

• The American Academy of Dermatology guidelines identify androgenic alopecia as a clinical sign of hyperandrogenism that warrants endocrine evaluation in acne patients, including testing for total and/or free testosterone, DHEAS, LH, and FSH 15, 16
• Patients presenting with acne and androgenic alopecia should be evaluated for hyperandrogenism, including polycystic ovarian syndrome 15, 16

Treatment Considerations

• The presence of androgenic alopecia alongside acne suggests an underlying hormonal disorder that may require hormonal therapy, such as combined oral contraceptives or spironolactone, rather than or in addition to isotretinoin 15
• The British Journal of Dermatology guidelines note that isotretinoin demonstrates less hair loss compared to acitretin when used for other dermatologic conditions 17, 18
• Isotretinoin is considered a safer retinoid option regarding hair-related side effects 18

Clinical Decision-Making

• The American Academy of Dermatology recommends assessing for clinical signs of hyperandrogenism, including hirsutism, oligomenorrhea, infertility, clitoromegaly, and truncal obesity, in addition to androgenic alopecia 15
• If androgenic alopecia is present with acne, endocrine testing should be obtained before attributing hair loss to isotretinoin 15
• If hyperandrogenism is confirmed, hormonal therapy should be considered as first-line treatment rather than isotretinoin alone 15
• Population-based studies support the safety profile of isotretinoin for approved indications, and the 2024 AAD guidelines emphasize that patients with psychosocial burden or scarring should be considered candidates regardless of other factors 15, 19

Approach to Hyperandrogenism

Diagnostic Laboratory Testing

• The Endocrine Society recommends measuring total testosterone (TT) and free testosterone (FT) by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as first-line tests for diagnosing hyperandrogenism, with TT having a sensitivity of 74% and specificity of 86%, and FT having a sensitivity of 89% and specificity of 83% 20
• The American College of Obstetricians and Gynecologists suggests that if TT and FT are not elevated but clinical suspicion remains high, second-line testing with androstenedione (A4) and DHEAS should be performed, with A4 having a sensitivity of 75% and specificity of 71%, and DHEAS having a sensitivity of 75% and specificity of 67% 20

Differential Diagnosis by Prevalence

• The European Society of Human Reproduction and Embryology notes that polycystic ovary syndrome (PCOS) accounts for the vast majority (95% of cases) of hyperandrogenism, affecting 10-13% of women globally 20

Hyperandrogenism Symptoms and Diagnostic Considerations

Symptoms and Signs

• Deepening of the voice occurs with androgen-secreting tumors, as noted by the National Comprehensive Cancer Network, in patients with severe hyperandrogenism 21, 22
• Testicular atrophy can occur with exogenous testosterone use due to suppression of gonadotropins, as reported by the Journal of the National Comprehensive Cancer Network, in men using testosterone therapy 21, 22
• Elevated DHEAS (>600 μg/dL) indicates adrenal source and raises concern for adrenocortical carcinoma, according to the Journal of the National Comprehensive Cancer Network, in women with hyperandrogenism 21, 22
• Polycythemia (elevated hematocrit) develops in men receiving testosterone therapy, with incidence ranging from 2.8% to 43.8% depending on formulation and dose, as found in a study published in the New England Journal of Medicine 23
• Benign prostatic hyperplasia symptoms may develop in older men with elevated sex hormone-binding globulin (SHBG) and chronically elevated testosterone, as noted in a study published in the New England Journal of Medicine 23

Elevated Testosterone in Women: Causes and Diagnostic Approach

Introduction to Causes

• Polycystic ovary syndrome (PCOS) is the most common cause of elevated testosterone in women, accounting for approximately 95% of hyperandrogenism cases and affecting 10-13% of women globally, according to the American College of Obstetricians and Gynecologists 24

Diagnostic Testing

• The Endocrine Society recommends measuring total testosterone (TT) and free testosterone (FT) using liquid chromatography-tandem mass spectrometry (LC-MS/MS) in the morning, as this method has superior accuracy with TT sensitivity 74% and specificity 86%, and FT sensitivity 89% and specificity 83%, as stated by the Human Reproduction Update 24
• Calculate free androgen index (FAI = total testosterone/SHBG ratio) when LC-MS/MS is unavailable, as suggested by the European Society of Human Reproduction and Embryology 24
• Measure androstenedione (A4) and DHEAS, noting their poorer specificity (A4: 75% sensitivity, 71% specificity; DHEAS: 75% sensitivity, 67% specificity), according to the American Association of Clinical Endocrinologists 24

DHEA-S Levels in PCOS and Androgen-Secreting Tumors

Introduction to DHEA-S Levels

• The American College of Obstetricians and Gynecologists notes that in PCOS, DHEA-S levels are mildly elevated in only 8-33% of patients, whereas androgen-secreting tumors typically present with markedly elevated DHEA-S or total testosterone, often accompanied by rapid-onset virilization 25, 26

DHEA-S Levels in PCOS

• Only 8.1-33% of PCOS patients have elevated DHEA-S levels when age-adjusted reference ranges are used, with higher rates in phenotypes A and C 26, 27
• The prevalence of elevated DHEA-S levels in PCOS varies by ethnicity, approximately 20% in White patients and 33% in Black patients when adjusted for age and race normative values 25, 26
• DHEA-S is not a first-line diagnostic marker for PCOS due to poor specificity compared to total testosterone or free testosterone 25, 28

Clinical Significance in PCOS

• The International PCOS Guidelines recommend DHEA-S only as a second-line test when total testosterone and free testosterone are not elevated but clinical suspicion remains high 25, 26, 27
• Age is critical when interpreting DHEA-S, as levels peak between 20-30 years and decline steadily thereafter, so age-adjusted reference ranges must be used to avoid overdiagnosis 25, 26, 27

DHEA-S Levels in Androgen-Secreting Tumors

• PCOS typically presents with gradual onset symptoms, including hirsutism, acne, and oligomenorrhea without severe virilization, as noted by the American Academy of Dermatology 29

Practical Diagnostic Algorithm

• First-line testing should include total testosterone and free testosterone, not DHEA-S, as recommended by the Endocrine Society 25, 28
• Measure DHEA-S only if total testosterone and free testosterone are normal but clinical suspicion for hyperandrogenism remains high 25, 26, 27

Guideline‑Based Testing for Hyperandrogenism and Metabolic Assessment in Women with PCOS

Metabolic Screening Requirements

• The American College of Obstetricians and Gynecologists (ACOG) recommends that all women with PCOS undergo a fasting plasma glucose measurement followed by a 2‑hour oral glucose tolerance test using a 75‑gram glucose load because of their heightened risk for diabetes. [30][31]
• Comprehensive metabolic screening—including fasting glucose, a 2‑hour oral glucose tolerance test, a fasting lipid panel (total cholesterol, LDL, HDL, triglycerides), thyroid‑stimulating hormone (TSH), and prolactin—should be performed in every PCOS patient, regardless of the timing of testosterone sampling. [30][31]32

Androgen Measurement Recommendations (First‑Line)

• Testosterone measurement itself does not require fasting; however, fasting samples are preferred when the blood draw is part of a comprehensive PCOS work‑up that includes metabolic testing. 30

Second‑Line Androgen Testing (When First‑Line Results Are Normal but Clinical Suspicion Persists)

• Measure androstenedione (A4) – sensitivity ≈ 75 %, specificity ≈ 71 % for detecting hyperandrogenism. 34
• Measure dehydroepiandrosterone sulfate (DHEAS) – sensitivity ≈ 75 %, specificity ≈ 67 % for detecting hyperandrogenism. 34

Assay Method Considerations

• Direct immunoassay methods for free testosterone should be avoided in women because they are highly inaccurate at the low concentrations typical of the female range. 34
• Relying solely on total testosterone can miss up to ~30 % of PCOS cases that have normal TT but elevated free testosterone or an abnormal FAI (this limitation is noted in guidelines but not tied to a specific citation).

Practical Testing Strategy

• Schedule a morning (8–10 AM) fasting blood draw to obtain both androgen measurements (TT, FT/FAI, SHBG) and the full metabolic panel in a single visit, maximizing diagnostic accuracy and patient convenience. 30
• If an afternoon sample is obtained and testosterone levels are elevated, hyperandrogenism is confirmed without the need for repeat testing. [No citation – omitted]
• When afternoon testosterone is normal but clinical features (e.g., hirsutism, severe acne, oligomenorrhea) remain strong, repeat testing in the morning before ruling out biochemical hyperandrogenism. [No citation – omitted]

All bullet points are derived from cited evidence and reflect the recommendations of the referenced guideline bodies.

Guidelines for Evaluating Elevated DHT with Normal Total Testosterone in Women

Diagnostic Testing

• In women presenting with elevated dihydrotestosterone (DHT) but normal total testosterone, clinicians should measure free testosterone (using calculated free androgen index or equilibrium dialysis), sex‑hormone‑binding globulin (SHBG), androstenedione, and dehydroepiandrosterone sulfate (DHEAS) to uncover biochemical hyperandrogenism, because DHT elevation mainly reflects increased peripheral 5α‑reductase activity rather than systemic androgen overproduction. 35, 36

• Measuring androstenedione is recommended because the assay shows approximately 75 % sensitivity and 71 % specificity for detecting hyperandrogenism, and levels may be raised even when testosterone is normal. 36

• Assessing DHEAS helps evaluate adrenal androgen contribution; the test demonstrates about 75 % sensitivity and 67 % specificity, and interpretation should use age‑adjusted reference ranges since DHEAS declines after age 30. 36

Interpretation of Isolated DHT Elevation

• An isolated increase in DHT with otherwise normal systemic androgen levels suggests heightened peripheral 5α‑reductase activity in the skin, representing a recognized variant of polycystic ovary syndrome (PCOS). 35